• cheap adobe creative suite cs3 buy windows 7 pro 64 price of windows xp service pack 2 photoshop cs3 price cheap adobe premiere elements buying rosetta stone stock best price office 2010 photoshop cs5 price australia cheap windows 7 home premium discount solidworks student price of adobe cs3 dreamweaver buy adobe flash for mac can you buy outlook separately buying microsoft office 2013 with product key cheap acrobat 9 pro
  • price of adobe audition guitar pro price buy lightroom 2 uk purchase office 2007 basic discount windows 7 home software buy cs4 design standard for mac purchase roxio popcorn cost of windows server 2008 cals order 2007 excel columns buy microsoft office 2010 professional product key purchase mac os x 10.6 best price iwork 08 windows 7 buy license buy naturally speaking software cheapest 2007 publisher

    Lymphoseek designated fast track status in head and neck cancer

    Wed, Dec 11, 2013

    Oral Cancer News

    Source: www.empr.com
    Author: press release

    Navidea announced that the FDA has granted Fast Track designation to Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer. Lymphoseek Injection is a novel, receptor-targeted, small-molecule radiopharmaceutical designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.

    Lymposeek Injection was evaluated in a prospective, open-label, multicenter, within-patient study (NEO3-06). It was designed to identify sentinel lymph nodes (SLNs) and determine the false negative rate (FNR) associated with Lymphoseek-identified SLNs relative to the pathological status of non-SLNs in head and neck and intraoral squamous cell carcinoma. The primary endpoint for the NEO3-06 trial was based on the number of subjects with pathology-positive lymph nodes following a multiple level lymph node dissection. A minimum of 38 subjects whose lymph nodes contained pathology-confirmed disease was required. Thirty nine subjects out of over 80 subjects enrolled were determined to have pathology-positive lymph nodes.

    Navidea intends to file the supplemental New Drug Application (sNDA) for Lymphoseek before the end of 2013. Lymphoseek is already approved for use in lymphatic mapping to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma.

    Print Friendly
    Be Sociable, Share!
    , , ,

    Leave a Reply

    You must be logged in to post a comment.